Deucravacitinib: Adverse Events of Interest Across Phase 3 Plaque Psoriasis Trials
In adults with plaque psoriasis treated with deucravacitinib, the cumulative incidence of AEIs remained comparable or decreased over 3 years of follow-up and aligned with comparison data for other antipsoriatic therapies.
Authors
- Thomas Scharnitz (ORCID: https://orcid.org/0000-0003-3070-4626)
- Jeffrey M. Sobell
- Joseph Frank Merola (ORCID: https://orcid.org/0000-0001-6514-4353)
- Laura K. Ferris (ORCID: https://orcid.org/0000-0003-3000-2165)
- Ying-Ming Jou
- Howard Sofen (ORCID: https://orcid.org/0000-0001-7789-6915)
- Carolin Daamen
- Julie Scotto
- John Vaile (ORCID: https://orcid.org/0000-0003-3540-0648)
- John Osborne (ORCID: https://orcid.org/0000-0002-6602-0894)
- Mark Lebwohl
Institutions
- University of North Carolina at Chapel Hill (US)
- Tufts Medical Center (US)
- University of California, Los Angeles (US)
- Bristol-Myers Squibb (United States) (US)
- Southwestern Medical Center (US)
- The University of Texas Southwestern Medical Center (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Dermatology and Therapy
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1007/s13555-025-01337-x
- Citations
- 3
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 2.39
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Sanofi
- Biogen
- Regeneron Pharmaceuticals
- Incyte
- Castle Biosciences
- Galderma
- Sun Pharma
- LEO Pharma